UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

NCT03224871 EARLY_PHASE1 COMPLETED

The advent of checkpoint blockade immunotherapy has revolutionized the management of metastatic non-small cell lung cancer (NSCLC). Despite the promising evidence for deep and durable responses with these agents the majority of patients fail to respond. The investigators hypothesize that a novel strategy combining radiotherapy and intralesional interleukin-2 (IL-2), a signaling molecule and member of the cytokine family involved in the activation of leukocytes and lymphocytes, may overcome resistance to checkpoint blockade therapy and offer significant clinical benefit to patients who fail to respond to checkpoint blockade alone. The investigators propose a microtrial testing the feasibility of a bold combinatorial immunotherapy strategy consisting of radiotherapy (RT), intralesional IL-2, and check-point blockade for metastatic non-small cell lung cancer patients who have progressed after checkpoint inhibition. IL-2 can upregulate PD-1 expression and activate T-cells.

Details

Lead sponsor	University of California, Davis
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	3
Start date	Fri Aug 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• METASTATIC NON-SMALL CELL LUNG CANCER

Interventions

• Intralesional IL-2
• Nivolumab
• Pembrolizumab
• Radiotherapy

Countries

United States